Higher Radiotherapy Doses But Fewer Treatment Sessions May Be Possible, Early Trial Data Suggest

Higher Radiotherapy Doses But Fewer Treatment Sessions May Be Possible, Early Trial Data Suggest
Prostate cancer patients may benefit from a new form of radiation therapy that delivers larger doses per session but in a much shorter treatment course, and when used in combination with a hydrogel spacer that helps to protect the rectum, early results from the ongoing SPORT trial suggest. Stereotactic Ablative Body Radiotherapy or SABR uses small, thin beams of radiation that are directed into the tumor from different angles. The treatment targets the tumor, which receives a high dose of radiation, while avoiding healthy tissues nearby. SABR allows for dose escalation, which conventional radiotherapy cannot, and patients can finish a full course of radiotherapy in five hospital visits instead of the standard 37. The SPORT trial (NCT03253978), which is now enrolling in Belfast, Ireland, is looking at the effects of SABR in patients with prostate cancer. The study, sponsored by the Belfast Health and Social Care Trust, aims to recruit 30 patients who will be given five doses of SABR. Before starting treatment, participants will also receive a minimally invasive hydrogel – called SpaceOAR hydrogel – which acts to create space between the rectum and the prostate, making it less likely that the rectum is exposed to radiation. According to Augmenix, its hydrogel makes it possible to use higher doses of radiation without affecting the rectum and surrounding tissues, leading to fewer complications. The company also reports that studies in the U.S. and Europe showed patients who received the SpaceOAR hydrogel had less rectal p
Subscribe or to access all post and page content.